Forwarded from RT News
This media is not supported in your browser
VIEW IN TELEGRAM
⚡️US Judge blocks vaccine requirement for federal contractors
A federal judge has agreed with Attorney General Wilson and blocked the vaccine requirement for federal contractors. (ABC affiliate)
The case was brought by Attorney General Wilson and Governor Henry McMaster, along with a number AGs from several states.
“Abuse of power by the Biden administration has been stopped cold again. The rule of law has prevailed and liberty is protected. When the President oversteps his authority the law is thankfully there to halt his misuse of power,” Attorney General Wilson said.
Subscribe to RT t.me/rtnews
A federal judge has agreed with Attorney General Wilson and blocked the vaccine requirement for federal contractors. (ABC affiliate)
The case was brought by Attorney General Wilson and Governor Henry McMaster, along with a number AGs from several states.
“Abuse of power by the Biden administration has been stopped cold again. The rule of law has prevailed and liberty is protected. When the President oversteps his authority the law is thankfully there to halt his misuse of power,” Attorney General Wilson said.
Subscribe to RT t.me/rtnews
This media is not supported in your browser
VIEW IN TELEGRAM
SOLAR ECLIPSE 2021 DEC
Regeneron Pharmaceuticals, Inc. (Regeneron); Pfizer, Inc. (Pfizer); and BioNTech SE and BioNTech US, Inc. (collectively BioNTech) for allegedly infringing U.S. Patent No. 10,221,221 (the ’221 patent),
The ‘221 Patent
The ’221 patent, titled “Monomeric Yellow-Green Fluorescent Protein from Cephalochordate,” was assigned to Allele and directed to high performance monomeric yellow-green fluorescent proteins. Although mNeonGreen was “Allele’s breakthrough in fluorescent protein technology,” Allele has many other achievements, including advances in “RNA interference, Fluorescent Proteins, Induced Pluripotent Stem Cells (iPSCs), Genome Editing, and camelid derived Single Domain Antibodies.” Most recently, Allele has also been “actively engaged in combating COVID-19, initiating impactful diagnostic and therapeutic platforms premised on speed, accuracy, and sensitivity.” Allele’s mNeonGreen technology has been licensed to hundreds of organizations and universities. As asserted by Allele, mNeonGreen “facilitates quick, targeted, and precise receptor research, including for potential therapeutics to treat COVID-19.”
The ’221 patent, titled “Monomeric Yellow-Green Fluorescent Protein from Cephalochordate,” was assigned to Allele and directed to high performance monomeric yellow-green fluorescent proteins. Although mNeonGreen was “Allele’s breakthrough in fluorescent protein technology,” Allele has many other achievements, including advances in “RNA interference, Fluorescent Proteins, Induced Pluripotent Stem Cells (iPSCs), Genome Editing, and camelid derived Single Domain Antibodies.” Most recently, Allele has also been “actively engaged in combating COVID-19, initiating impactful diagnostic and therapeutic platforms premised on speed, accuracy, and sensitivity.” Allele’s mNeonGreen technology has been licensed to hundreds of organizations and universities. As asserted by Allele, mNeonGreen “facilitates quick, targeted, and precise receptor research, including for potential therapeutics to treat COVID-19.”